Vyteris Announces Agreement for Additional Funding

FAIR LAWN, NJ--(Marketwire - March 25, 2009) - Vyteris, Inc. (OTCBB: VYTR), developer of the first FDA-approved active transdermal drug delivery system and a leader in active transdermal drug delivery technology, announced that its development partner, Ferring Pharmaceuticals Inc., further deepened its commitment to Vyteris by agreeing to fund the first half of the 2009 development budget for its joint partnership with Vyteris in developing a pulsatile delivery of a peptide hormone for treatment of infertility in women.

"We are appreciative of Ferring's continued support and confidence in Vyteris through this latest funding initiative. In conjunction with this funding, Vyteris will continue to preserve cash by focusing on the needs of the company's ongoing project with Ferring, and to seek other product development partnership opportunities. Vyteris is maximizing efficient use of its resources to capitalize upon all of its potential growth opportunities," said Dr. Haro Hartounian, chief executive officer of Vyteris.

"This agreement reinforces Ferring's continued commitment to working with firms with innovative technologies which we might harness for our portfolio," said Wayne Anderson, chief executive officer of Ferring. "We have had a productive development relationship with Vyteris and plan on continuing our joint efforts on behalf of patients looking for solutions."

The agreement calls for Ferring to pay the first half of the budgeted costs in an amount up to $3.3 million, with cash proceeds committed to the infertility project, and Vyteris to fund the second half of the 2009 development budget. Ferring also bought Vyteris' patch manufacturing machine for a $1.0 million purchase price and entered into a ten year agreement to lease the equipment back to Vyteris.

About Vyteris

Vyteris, Inc. is a specialty pharmaceutical company developing and commercializing innovative technology for controlled delivery of peptide and small molecule therapeutics. Vyteris' first product, LidoSite®, which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA-approved active patch. Vyteris' proprietary transdermal drug delivery technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. For more information, please visit us at www.vyteris.com.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology, orthopaedic and infertility products in the U.S. markets. They include: EUFLEXXA®, (1% sodium hyaluronic acid), BRAVELLE® ( urofollitropin for injection, purified), MENOPUR® and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, ACHTREL® (corticorelin ovine triflutate for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), and DESMOPRESSIN.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology and infertility. For more information, please visit www.FerringUSA.com.

Vyteris Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "anticipate," "intend," "plan," "may," "will," "could," "would," "should," "believes," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-K and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.

Contact Information: Contacts: Joseph Himy Chief Financial Officer Tel: (201) 300-1160 James Lee The Lee Strategy Group, Inc. Tel: (310) 229-5771 Email: